Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

A new daily weight loss pill can help patients with type 2 diabetes lose more weight and better control their blood sugar ...

Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 ...

Researchers from Queen Mary University of London have found that a medication originally developed for glycemic control can reverse serious heart damage—not by controlling blood sugar as originally ...

Orforglipron carried more side effects, however ...

A new daily pill could offer a major breakthrough for people living with type 2 diabetes and struggling with weight management ...

Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), ...